Teva Tumbles as Price Deflation Catches Up With Imports — Panjiva


Teva Tumbles as Price Deflation Catches Up With Imports

Earnings 406 Health Care 169 U.S. 4092

Generic drug manufacturer Teva cut its full year revenue guidance by 5%, in part because of drug price deflation. Its stock price dropped 23% in response. Falling drug prices have been evident in U.S. import data for some time. Panjiva data shows average prices per kg fell 25% in the three months to May 31, led by a 40% drop in cardiovascular treatments. Teva’s performance was otherwise solid, with its exports of generics to the U.S. having risen 8% in volume terms in the second quarter, helping revenue growth of 20%.

PANJIVA RESEARCH is a service provided by Panjiva, Inc. ("Panjiva") to relevant global subscribers, and are deemed to be Panjiva "Services" subject to the Panjiva Terms & Conditions of Use. Information contained within or made available via the Services is for informational purposes only and nothing in the Services shall constitute or be construed as an offering of financial instruments, or as investment advice or recommendations by Panjiva, Inc. or its affiliates of an investment strategy or whether to "buy", "sell" or "hold" an investment. The Services may include views and commentary about customers of Panjiva. No aspect of the Services is based on consideration of your individual circumstances, and you should determine on your own whether you agree with the information contained within or made available via the Services. Employees involved in Panjiva Research may hold positions in securities analyzed or discussed in the Services. Panjiva does not make any express or implied warranties, representations, endorsements or conditions with respect to the Services and the information contained within or made available via the Services, including without limitation, warranties as to the usefulness, completeness, accuracy, currentness, reliability or sufficiency of any information (including, without limitation, conclusions, statements, opinions, estimates, forecasts or projections of any kind) and expressly disclaims any implied warranties. Neither this disclaimer nor any of its contents may be forwarded or redistributed without the prior written consent of Panjiva. © 2020 S&P Global. All Rights Reserved.